Previous 10 | Next 10 |
Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company with a mission to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operating results for the first quarter ended March 31, 2022. “By entering into a merg...
NEW YORK, NY / ACCESSWIRE / April 29, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: SilverBow Resources, Inc. (NYSE:SBO...
NEW YORK, NY / ACCESSWIRE / April 21, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Tivity Health, Inc. (NASDAQ:TVT...
GlaxoSmithKline has agreed to buy out Sierra Oncology for $1.9bn - Sierra is attempting to bring Momelotinib to market after strong Phase 3 results in Myelofibrosis. Momelotinib could be a blockbuster, with peak sales expectations of $1.7bn. Activist Investor Elliott Management is...
Thoma Bravo continued its binge of software acquisitions last week by entering into an agreement to acquire SailPoint Technologies. Kaseya, a provider of unified IT management and security software, entered into a definitive agreement to acquire Datto Holdings for $6.2 billion. Wi...
5 Top Biotech Stocks To Watch Today The stock market offers plenty of opportunities for investors. Some industries would still catch the attention of investors regardless of the broader market sentiment. A prime example would be biotech stocks . Now, why is that so? For starters...
Palm Beach, FL – April 14, 2022 – FinancialNewsMedia.com News Commentary – CAR-T therapy is a sort of treatment in which a patient’s T cells which is a type of immune system cell, are genetically modified to attack cancer cells in the lab. T cells are...
Stocks rebounded from recent weakness on Wednesday, as bargain hunting among beaten-down growth stocks pushed the major averages higher. The Nasdaq led the advance, climbing about 2% on the day. Travel stocks contributed to the upswing. An upbeat earnings report from Delta Air Lines raised ho...
Sierra Oncology ( NASDAQ: SRRA ) shares traded significantly higher after announcing the acquisition by GlaxoSmithKline PLC ( LON: GSK ) for $55 a share in cash. That represents a total equity value of $1.9 billion, attributed mainly to SRRA’s Momeloti...
Gainers: Kaleido Biosciences (KLDO) +114%. Antares Pharma (ATRS) +49%. Sierra Oncology (SRRA) +39%. HighPeak Energy (HPK) +29%. Biofrontera (BFRI) +30%. Turning Point Therapeutics (TPTX) +27%. Aterian (ATER) +25%. Hallador Energy (HNRG) +23%. Crinetics Pharmaceutical (CRNX) +20%. Exscientia (...
News, Short Squeeze, Breakout and More Instantly...
Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEO John Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading en...
– Submission seeks approval of momelotinib for the treatment of myelofibrosis – Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submi...